Primary outcome
What NCT03158805 measured first
| Active Drugn=29 | Placebon=31 |
|---|---|
| -3.3(5.2) | 0.2(4.2) |
Phase 2 · Liraglutide
NCT03158805 trial results
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
Percent Change in Body Weight (% change), 40 week. Active Drug: -3.3; Placebo: 0.2.
- Participants
- 60
- Status
- completed
- Completed
- 2023-01-01
- Sponsor
- Lindner Center of HOPE
As posted on ClinicalTrials.gov (NCT03158805), updated at source Mar 12, 2025. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in NCT03158805
Percent of participants affected, Through study completion, for the total duration of the trial, including up to 27 days of screening , the 40 study treatment weeks and one week of follow up. The most common events the registry lists.
| Event | Active Drug | Placebo |
|---|---|---|
| Any serious event | 0% | 6.5% |
| Nausea | 65.5% | 45.2% |
| Constipation | 41.4% | 9.7% |
| URI | 34.5% | 19.4% |
| Heartburn | 34.5% | 6.5% |
| Headache | 20.7% | 29% |
| Mood dysregulation | 24.1% | 25.8% |
| Gastroenteritis | 24.1% | 16.1% |
| Musculoskeletal pain | 24.1% | 16.1% |
| Injection site irritatation | 17.2% | 19.4% |
| Sleep disturbance | 17.2% | 16.1% |
The trial
How NCT03158805 was run
Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display greater efficacy as compared to placebo in decreasing body weight in patients with BP who are obese or overweight. To prove this hypothesis, investigators will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP. The investigators have chosen BP rather than another SMI because it is the most common SMI (more common than schizophrenia or schizoaffective disorder) and has a particularly strong association with obesity.
- Active drug: LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
- Placebo: Placebo (no active drug)
Who could join the trial
Inclusion Criteria: 1. Men and women, ages of 18-65 years, inclusive. 2. Participants will have a DSM-5 bipolar disorder that is clinically stable. 3. Participants will have received a stable major psychotropic drug regimen (except for minor dosage adjustments) for at least 3 months prior study entry. Major psychotropic drugs are antipsychotics, mood stabilizers, and antidepressants. Subjects may have had changes in adjunctive benzodiazepines and hypnotic agents. 4. Participants will be obese (defined as a BMI ≥ 30 mg/kg2) or overweight (defined as BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. 5 Participants in treatment for a weight-related comorbidity (hypertension, type 2 diabetes, and/or dyslipidemia) must be on a stable and allowed treatment regimen for that condition for at least 3 months prior to study enrollment. 6 Participants will be able to provide informed consent before any trial-related activities. Exclusion Criteria: 1. Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. The following are considered to be adequate methods of birth control: 1.Intrauterine device (IUD); 2. Barrier protection; 3.Contraceptive implantation system (Norplant); 4.Oral contraceptive pills; 5. A surgically sterile partner; and 6. Abstinence. Women who are \> 2 years post-menopausal or surgically-sterile are not considered of childbearing potential. All female participants will have a negative pregnancy test prior to randomization. 2. Participants who have made a suicide attempt in the last 10 years, who are displaying clinically significant psychotic features, suicidality, or homicidality on mental status examination, or who have suicidal ideation or behavior as assessed with the C-SSRS. 3. Participants who are receiving behavioral weight loss treatment (BWLT) (e.g., Weight Watchers) that was begun within the 3 months before study entry. Participants who are receiving BWLT that was started 3 months prior to the beginning of the study will be allowed to continue to receive their BWLT during the trial only if they have had no weight loss in the past 3 months and they agree to not make any changes in the frequency or nature of their BWLT during the course of the drug trial. 4. A DSM-5 diagnosis of a substance-related or addictive disorder (except a tobacco-related disorder) within the 3 months prior to enrollment. 5. A DSM-5 diagnosis of dementia, a psychotic disorder, or a depressive disorder. 6. History of any psychiatric disorder which might interfere with a diagnostic assessment, treatment, or compliance. 7. Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, neurological, metabolic, endocrine, or other systemic disease. Clinically stable hypertension, type 2 diabetes, or dyslipidemia are not exclusionary. 8. Have a history of a structural cardiac abnormality,...
Published papers
Papers from NCT03158805
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.